Recombinant Human EMAP-II protein

SKU: CD01877

Size:5 ug

Background:Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.

Research_area:Immunology

Purity:> 98 % by SDS-PAGE and HPLC analyses.

Source:Escherichia coli.

Full product name:Recombinant Human Endothelial-Monocyte Activating Polypeptide II

Biological activity:Fully biologically active when compared to standard. The ED5 as determined by the apoptotic effect using serum free human MCF-7 cells is less than 4 ng/ml, corresponding to a specific activity of > 2.5 × 14 IU/mg.

Synonyms:EMAP-II, p43; HLD3; EMAP2; SCYE1; EMAPII,AIMP1,Human

Endotoxin:Less than 1 EU/μg of rHuEMAP-II as determined by LAL method.

Storage:-20ºC

Sequence:SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK

uniprot accession:O95834

Molecular weight:Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

Formulation:

Reconstitution:Lyophilized from a .2 μm filtered concentrated solution in PBS, pH 7.4.